207110-72-3

Upstream product

• 701-45-1 2-bromo-1-fluoro-4-nitrobenzene 
• 75-33-2 2-propanethiol 

Downstream Products

• 1610786-70-3 C₄₇H₆₁N₅O₁₁S 
• 1520082-83-0 C₄₂H₅₁N₅O₉S 
• 1520082-84-1 C₄₃H₅₁F₂N₅O₁₀S 
• 1520082-85-2 C₄₄H₅₅N₅O₁₁S 
• 1520082-86-3 C₄₃H₅₂ClN₅O₁₀S 
• 1520082-87-4 C₄₃H₅₂FN₅O₁₀S 
• 1520082-88-5 C₄₃H₅₂FN₅O₉S 
• 1520082-89-6 C₄₃H₅₂FN₅O₁₀S 
• 1520082-90-9 C₄₄H₅₃F₂N₅O₁₀S 
• 1520082-91-0 C₄₄H₅₄FN₅O₁₀S 
• 900174-34-7 tert-butyl 2-(2-(isopropylsulfonyl)-5-nitrophenyl)-1H-pyrrole-1-carboxylate 
• 900174-68-7 (S)-tert-butyl 2-(5-amino-2-(isopropylsulfonyl)phenyl)pyrrolidine-1-carboxylate 
• 900174-67-6 (R)-tert-butyl 2-(5-amino-2-(isopropylsulfonyl)phenyl)pyrrolidine-1-carboxylate 
• 900174-71-2 (R)-methyl (4-(isopropylsulfonyl)-3-(pyrrolidin-2-yl)phenyl)carbamate hydrochloride 

Relevant academic research and scientific papers

BENZAMIDE FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS

The present invention provides novel benzamide derivatives of Formula (I): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein the variables A, W, Y, Z, R8, and R9 are as defined herein. These compounds are selective inhibitors of factor VIIa which can be used as medicaments.

BICYCLIC LACTAM FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS

The present invention provides novel bicyclic lactams derivatives, and analogues thereof, of Formula (I): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein the variables A, B, C, W, Y, Z1, Z2, Z3, Z4, R8, and R9 are as defined herein. These compounds are selective inhibitors of factor VIIa which can be used as medicaments.

PHENYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS

The present invention relates generally to phenylglycinamide derivatives that inhibit serine proteases. In particular it is directed to novel phenylglycinamide derivatives, and analogues thereof, which are useful as selective inhibitors of serine protease enzymes of the coagulation cascade; for example thrombin, factor VIIa, factor Xa, factor XIa, factor IXa, and/or plasma kallikrein. In particular, it relates to compounds that are factor VIIa inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of using the same.